Long-term hydromethylthionine treatment is associated with delayed clinical onset and slowing of cerebral atrophy in a pre-symptomatic P301S MAPT mutation carrier

Bentham, PeterStaff, Roger T.Schelter, Bjoern O.Shiells, HelenHarrington, Charles R.Wischik, Claude M.2021-11-162021-11-162021-09-28Bentham, P, Staff, R T, Schelter, B O, Shiells, H, Harrington, C R & Wischik, C M 2021, 'Long-term hydromethylthionine treatment is associated with delayed clinical onset and slowing of cerebral atrophy in a pre-symptomatic P301S MAPT mutation carrier', Journal of Alzheimer's Disease, vol. 83, no. 3, pp. 1017-1023. https://doi.org/10.3233/JAD-2103901387-2877ORCID: /0000-0003-2250-3920/work/173415908https://hdl.handle.net/2164/17505ACKNOWLEDGMENTS We thank the patient for permitting publication of the present report. Authors’ disclosures available online (https://www.j-alz.com/manuscript-disclosures/21-0390r1).7926810engSDG 3 - Good Health and Well-beingFrontotemporal dementiahydromethylthionineleucomethylthioniniummicrotubule-associated protein tauP301SR MedicineGeneral NeuroscienceClinical PsychologyGeriatrics and GerontologyPsychiatry and Mental healthRLong-term hydromethylthionine treatment is associated with delayed clinical onset and slowing of cerebral atrophy in a pre-symptomatic P301S MAPT mutation carrierJournal article10.3233/JAD-210390http://www.scopus.com/inward/record.url?scp=85116494713&partnerID=8YFLogxK833